To Boost Or Not To Boost? Pfizer At Odds With US FDA
Pfizer Unphased By Apparent Pushback
US regulators indicate that authorizing booster shots is not a priority - but Pfizer still plans to seek an EUA in the fall.
You may also be interested in...
In search of a differentiated approach, candidate aims to boostT-cell immune responses via a subcutaneous and oral vaccine combination.
Arriving two to three months later than planned, Novavax’s nanoparticle-based vaccine is still a welcome addition to the field, for both rich and poor countries.
Investors were spooked by mixed results from Alector’s lead candidate but the company’s CEO hit out at ‘hype’ around the biomarker